Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.60% | 175.62% | 636.99% | 11,070.12% | 13,698.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.60% | 175.62% | 636.99% | 11,070.12% | 13,698.99% |
| Cost of Revenue | 74.17% | 145.16% | 271.22% | 734.90% | 903.59% |
| Gross Profit | 34.52% | 314.50% | 551.95% | 486.44% | 686.81% |
| SG&A Expenses | -0.03% | 13.05% | 27.73% | 49.88% | 42.75% |
| Depreciation & Amortization | -1.91% | 86.62% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.30% | 27.06% | 32.55% | 30.28% | 21.14% |
| Operating Income | -0.74% | 4.33% | 10.59% | 14.69% | 14.17% |
| Income Before Tax | -4.81% | 4.28% | 12.63% | 16.70% | 16.20% |
| Income Tax Expenses | 26.77% | 88.66% | 103.20% | 33.33% | 18.71% |
| Earnings from Continuing Operations | -5.05% | 3.02% | 11.43% | 16.52% | 16.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.05% | 3.02% | 11.43% | 16.52% | 16.18% |
| EBIT | -0.74% | 4.33% | 10.59% | 14.69% | 14.17% |
| EBITDA | -1.29% | 7.05% | 13.40% | 18.27% | 18.56% |
| EPS Basic | 13.67% | 19.63% | 27.10% | 32.07% | 31.46% |
| Normalized Basic EPS | 15.72% | 22.44% | 28.71% | 32.76% | 31.71% |
| EPS Diluted | 13.67% | 19.63% | 27.10% | 32.07% | 31.46% |
| Normalized Diluted EPS | 15.72% | 22.44% | 28.71% | 32.76% | 31.71% |
| Average Basic Shares Outstanding | 23.22% | 19.46% | 20.21% | 22.51% | 23.33% |
| Average Diluted Shares Outstanding | 23.22% | 19.46% | 20.21% | 22.51% | 23.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |